(Q48620677)

13 February 2018

title

Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study (English)

1 reference

13 February 2018

1 reference

1 reference

Orazio Caffo

1

1 reference

13 February 2018

Lucia Fratino

2

1 reference

13 February 2018

Roberto Barbieri

3

1 reference

13 February 2018

Alessandra Perin

4

1 reference

13 February 2018

Thomas Martini

5

1 reference

13 February 2018

Teodoro Sava

6

1 reference

13 February 2018

Romana Segati

7

1 reference

13 February 2018

Emanuela Vaccher

8

1 reference

13 February 2018

Franco Bernardo Bassan

9

1 reference

13 February 2018

Antonello Veccia

10

1 reference

13 February 2018

Giovanni Pappagallo

11

1 reference

13 February 2018

Enzo Galligioni

12

1 reference

13 February 2018

publication date

31 July 2011

1 reference

13 February 2018

published in

Urologic Oncology

1 reference

13 February 2018

volume

31

1 reference

13 February 2018

issue

2

1 reference

13 February 2018

page(s)

180-186

1 reference

13 February 2018

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Measuring the clinical response. What does it mean?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Molecular basis of antifolate resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.11.012

10.1016/J.UROLONC.2010.11.012

7 January 2021

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018